News Release

For further information please contact:

Dr Werner Lanthaler
Chief Executive Officer

+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.com

Evotec AG
Schnackenburgallee 114
22525 Hamburg
Germany
www.evotec.com

Evotec and Vifor Pharma Sign Major Cooperation Agreement

- **Development of preclinical candidate in the field of anaemia**
- **Evotec to provide integrated biology, chemistry and preclinical development activities**
- **Project worth in excess of EUR 5.5 million**

Hamburg, Germany – 2 February 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has signed an agreement with Vifor Pharma. Evotec will provide and project manage the discovery activities to identify a preclinical candidate for the treatment of anaemia. Due to confidentiality reasons both companies will not reveal further details about the research project.

The agreement applies Evotec's integrated drug discovery expertise and technologies to progress novel small molecules for the treatment of anaemia from discovery into lead optimisation.

Evotec will use scientists based at both its European and Indian sites covering *in vitro* biology, medicinal chemistry, *in vitro* and *in vivo* pharmacology and the programme will be funded through research funding and success based milestones.

Dr Werner Lanthaler, CEO of Evotec, commented: "This agreement represents a great step forward in our business model, as we are committed to identifying a preclinical candidate within an agreed budget. This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate to Vifor Pharma and clearly demonstrates the complete integrated drug discovery capability we have."

"We have a high regard for Evotec's drug discovery and development expertise and the capabilities and technologies they will use to progress our project. They have a proven expertise in drug discovery and development and we look forward to achieving success with Evotec" **said Dr David Ebsworth, CEO at Vifor Pharma**.

About Anaemia
Anaemia is a condition in which the haemoglobin concentration in the blood is below a defined level, resulting in a reduced oxygen-carrying capacity of red blood cells.
Iron deficiency is the most common nutritional disorder in the world and the most common cause of anaemia. There are an estimated 700 million people in the world with iron deficiency anaemia. Symptoms of iron deficiency/anaemia are fatigue, pallor, hair loss, irritability, weakness, brittle or grooved nails etc.

About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com.

About Vifor Pharma
Vifor Pharma, the Pharma business sector of the Galenica Group, researches, develops, manufactures and markets pharmaceutical products, with focus on the treatment of anaemia, where Vifor Pharma is one of the leading companies. Vifor Pharma also conducts clinical studies for the application of medications for the treatment of various autoimmune diseases. Further, Vifor Pharma manufactures prescription and OTC products developed within the company or produced or sold under license, and markets them on international markets. Vifor Pharma is headquartered in Switzerland (Zurich).
Additional information on Vifor Pharma can be found at www.viforpharma.com

Forward-looking statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning our strategic collaborations, our regulatory, clinical and business strategies, the progress of our clinical development programmes and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that

we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.